Skip to content
Homepage
Author:
Nanoscope Therapeutics
Posted Date:
May 29, 2026
Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
Nanoscope Therapeutics
May 29, 2026
Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting
Nanoscope Therapeutics
May 27, 2026
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
Nanoscope Therapeutics
May 24, 2026
Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness
Nanoscope Therapeutics
May 22, 2026
Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration
Nanoscope Therapeutics
May 21, 2026
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
Nanoscope Therapeutics
May 20, 2026
Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting
Nanoscope Therapeutics
February 24, 2026
